Amarillo, Texas, May 20, 2009 — Amarillo Biosciences, Inc. (AMAR) (OTCBB: AMAR) today announced that it has selected Accelovance, Inc., a clinical research organization (CRO) based in Rockville, MD, to conduct a human clinical study of the company’s oral interferon product during the upcoming 2009/2010 influenza season in the US. This new Phase 2 clinical trial will be a follow-up to the ongoing study at the University of Western Australia being conducted by Dr. Manfred Beilharz and colleagues, which is expected to show that lozenges containing a low dose of interferon-alpha can prevent infection or reduce the severity of infection with influenza and other common respiratory viruses when taken once a day during a typical winter cold/flu season. The study in Australia is well under way, with over 100 healthy adult volunteers screened to date for inclusion in the trial.

Amarillo, Texas, April 27, 2009 — Amarillo Biosciences, Inc. (AMAR) (OTCBB: AMAR) today announced that it has issued the following Letter to Shareholders addressing oral interferon and the recent swine flu outbreak. This information is being sent to governments, influenza experts and other individuals because of the urgency of the present influenza outbreaks in Mexico, Canada, New Zealand and the United States.